[Ranitidine VUFB in the treatment of peptic ulcer].
The authors tested in an open clinical investigation in a group of 30 patients the therapeutic effectiveness and tolerance of the newly developed preparation Ranitidine VUFB in the treatment of peptic gastroduodenal ulcers. The preparation was administered to patients with an endoscopically confirmed diagnosis, 300 mg/day by the oral route, for a period of 4 weeks. A positive and rapid effect on regression of subjective complaints was observed and a very favourable effect on healing of the ulcer. After four weeks complete healing of gastroduodenal ulcers was recorded in 73% of the patients, in another 10% marked diminution of the ulcer occurred with a tendency to heal. The preparation was tolerated very well by the patients and there were no serious side-effects. The assembled results are comparable with data on similar preparations prepared abroad and Ranitidine VUFB should be included among desirable and useful anti-ulcer drugs.
Steinigerová
J
J
I. interní klinika LF UK Plzen.
Kratochvíl
J
J
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy*; D011899:Ranitidine / Q000627:therapeutic use*
D011899:Ranitidine